Opioid pain medicines: preserve pain care and notice a problem

A person can fear two things at once: being left in pain and becoming dependent on a medicine. When the discussion offers only “put up with it” or “take it and ask no questions,” it removes what matters most: the chance to assess a particular treatment and get help for a particular problem.

An opioid pain medicine can provide real relief and help someone move, sleep or work. That does not make every prescription safe for an indefinite period. Yet neither treatment duration nor the existence of a prescription supplies a diagnosis. This article asks how to preserve pain care while discussing possible opioid use disorder in time.

1. Pain and opioid use need two separate conversations

“I feel better” and “I struggle to manage how I take it” can both be true. The discussion needs to establish what pain is being treated, what has improved, what unwanted effects have appeared and how the person uses the medicine. Work and everyday activity may genuinely improve; they do not establish a measured improvement in thinking or the absence of a disorder.

Discussing benefit should not become an examination in which the patient must justify deserving pain relief. Discussing risk should not disappear because the medicine was prescribed. CDC recommends assessing the benefits and risks of continuing therapy together. This is clinical work with an individual, rather than a universal answer for every kind of pain.

2. Physical adaptation and opioid use disorder are different concepts

Tolerance means a change in the response to a substance with repeated exposure. Physical dependence in a medication context means bodily adaptation: reducing or stopping the medicine may bring withdrawal symptoms. These phenomena can exist without a full use disorder. Do not try to test them yourself by changing treatment or deliberately missing medicine.

CDC's description of OUD diagnosis includes a narrow qualification: tolerance and withdrawal are not counted as the corresponding criteria in people taking opioids solely under appropriate medical supervision. This qualification concerns opioids specifically; it does not make any prescription immune to any problem. Other signs still need assessment.

OUD stands for opioid use disorder. It is not another name for severe pain, lengthy treatment or a loved one's worried description that someone is “hooked.” Physical adaptation also does not make someone at fault for feeling unwell without the medicine.

3. What to tell a health care professional

Reasons for a conversation may include repeatedly taking a medicine differently from the prescription, difficulty controlling use, strong craving, consequences for relationships or responsibilities, and continued use despite known harm. Circumstances and a combination of signs matter, rather than one item on a list. This article does not give the reader or a relative a home diagnostic scale.

If the previous effect changes, pain increases or fear of being without medicine appears, do not decide in advance that “it is just addiction.” Pain, unwanted effects, physical adaptation and possible OUD may need assessment. The reverse is also unhelpful: pain cannot explain away every known dangerous action and close the discussion of consequences.

A concrete account — “I took it differently from what we agreed, and now I am afraid to talk about it” — is more useful than a forced admission of “I am addicted.” Help can begin before a final diagnosis and without agreement with the family's entire interpretation.

4. Assessing OUD should preserve pain treatment

CDC specifically emphasizes ongoing pain management for people who have both pain and OUD. A plan may include suitable nonmedication approaches, other medicines and treatment of the disorder itself. Some OUD medicines can also help with concurrent pain; the particular choice requires clinical assessment.

Beneficial prescribed OUD treatment is not a “failure of sobriety” or proof that the patient has merely exchanged one addiction for another. Treatment also should not be reduced to a promise that one medicine will necessarily resolve all pain and every difficulty.

You do not need to endure pain that has not been discussed in order to demonstrate willpower. Nor should you choose a replacement yourself, stop a medicine or compensate for its effect with another substance. Changes to therapy are planned with a professional; this article supplies no schedule for making them.

5. Long-term treatment calls for review

A follow-up conversation should address actual benefit, pain, everyday functioning, unwanted effects and available care options. Continuing treatment should remain a considered decision, rather than happen solely because a first prescription was issued in the past. Review does not mean that everyone must stop treatment.

In its communication of 31 July 2025, FDA required updated information on the risks of long-term opioid pain medicine use. Two observational studies were among the grounds for the action. Their estimates cannot be converted into a personal forecast for any patient or evidence that treatment is safe indefinitely.

FDA also warns against abruptly stopping or rapidly reducing use when physical dependence may be present. Do not decide on treatment through a home experiment of “let us see whether I can manage without it.” A dangerous condition needs urgent help, rather than waiting for an ordinary prescription review.

6. Breathing and responsiveness come before a complete history

Opioids taken with alcohol, benzodiazepines and some other central nervous system depressants may increase overdose risk. This does not mean all medicines or combinations have the same danger. Ask a doctor or pharmacist about the compatibility of particular prescriptions, also disclosing nonprescribed substances.

If someone does not respond, is hard to wake, or has slow, shallow or difficult breathing, seek immediate local emergency medical help. Do not wait for an exact composition, an admission of use or completed notes. NHS's general poisoning guidance also distinguishes urgent assessment of suspected poisoning from a dangerous condition requiring immediate help.

Tell the dispatcher what is already known and follow their instructions. Do not attempt to “balance” the effect with another substance. In advance, you can discuss access to opioid overdose reversal medicines and training with a professional; that discussion does not replace an emergency call when someone is in danger.

7. Systemic failures do not make every patient guilty

There are documented examples of failures in opioid promotion and oversight in the United States. On 24 November 2020, Purdue Pharma LP pleaded guilty to three criminal conspiracy charges. Admissions included misleading the DEA and payments that encouraged prescriptions. This concerns a particular company, a particular proceeding and a dated event.

Apart from the corresponding criminal admissions, the civil claims in that announcement were identified as allegations without a determination of civil liability. The case does not establish that every prescriber acts dishonestly, every patient receiving long-term treatment has an addiction, or every continuation of therapy is commercial retention. System responsibility and a person's need for treatment belong in the same conversation.

8. Prepare a first contact using facts already known

The five fields below are optional aids for a conversation, created for this article rather than a clinical scale. You do not need to collect everything, reconstruct unknown details or postpone help until the account is complete.

1. Pain and benefit. What is being treated, what has genuinely become easier and what functions have changed?

2. Known prescriptions. What medicines were prescribed, by whom, and what other substances are already known? Do not guess an unknown composition.

3. Changes and consequences. What has changed, and what difficulties or dangerous episodes can you describe concretely?

4. Concerns. What frightens you: pain, withdrawal, judgment, losing the medicine or the cost of care?

5. An accessible contact. Who could you approach, and what gets in the way: money, language, transport, an appointment or a previous bad experience?

An initial action could be to request a prescription review from the treating professional or ask about an available local care route. SAMHSA suggests preparing questions for an appointment; the American resource cannot guarantee such a service in every country. Ask the particular service about cost, language and privacy rules. If one route is unavailable, look for another feasible contact rather than treat a refusal as proof that you have no entitlement to help.

9. Loved ones help within their own responsibility

A loved one can offer accompaniment, help communicate agreed information or describe specific harm they have noticed. This does not authorize diagnosing someone at a distance, secretly controlling an adult's medicines or demanding an admission as a condition of support. Disagreement with the family is not an OUD sign in its own right; harm that was caused should not be concealed behind the language of treatment.

SAMHSA addresses support and boundaries for the helper. A relative does not have to be the sole rescuer or guarantee the outcome of treatment. A child should not monitor an adult's medicine-taking, check their breathing on a schedule or keep them from using substances. Safe medicine storage and arranging care are adult responsibilities.

Violence, threats or immediate danger need a separate safe route and local emergency help. Consent and involvement are discussed in the particular circumstances and under local rules; this article offers no universal law on forced treatment. You can approach care with doubts, pain and fear. Perfect determination, a new purpose in life and a “strong mind” are not admission requirements for medical help.

Sources

S1. CDC. Continuing Opioid Therapy. 7 May 2024. Clinical guidance on shared review of continuing treatment; not a complete guideline for every pain context.

S2. CDC. Opioid Use Disorder: Diagnosis. 16 April 2024. OUD description; the tolerance and withdrawal qualification is limited to opioids taken solely under appropriate medical supervision.

S3. CDC. Opioid Use Disorder and Pain Management. 9 April 2024. Care for co-occurring pain and OUD.

S4. FDA. Updating opioid prescribing information regarding long-term use. Communication dated 31 July 2025. Regulatory overview of risk and safety; the underlying studies were not separately read in full.

S5. NHS. Poisoning. Reviewed by NHS on 12 June 2025. General poisoning guidance; British numbers were not transferred into a universal route.

S6. U.S. Department of Justice, District of New Jersey. Purdue Pharma admits guilt in fraud and kickback conspiracies. 24 November 2020. Announcement of a guilty plea and separately identified civil claims; not the whole court archive or verification of actual payments.

S7. SAMHSA. How to Set Up an Appointment. 24 April 2023 in the displayed official text. The displayed expanded search text was read; direct access was restricted.

S8. SAMHSA. Taking Care of Yourself. 24 April 2023 in the displayed official text. Helper support and boundaries; the displayed expanded search text was read.

About the authors

Andrey Zarinsh is the author and founder of United Wisdom. He explores inner transformation, the unity of traditions, intercultural dialogue and contemporary spiritual discipline. Instagram: @andrey.zarinsh.

Maria Evilkut is a co-author of United Wisdom. Alongside her research, she seeks to test these ideas in practice and observe how principles of unity and mutual understanding work in real life between people and cultures. Instagram: @ilkutki.

Content reviewed: 14 October 2026. English edition.